October 2020

We are pleased to welcome Ada Kruisbeek as Chair of the scientific advisory board. She brings a wealth of expertise and experience in the field of immunology and cancer immunotherapy.

Ada has been a long-standing researcher at the NIH in the US before becoming Head of the Department of Immunology of the Netherlands Cancer Institute and Professor of Immunology at the Free University Amsterdam.

She founded DC-Prime and became their CEO. Currently Ada serves as an advisor to DC-Prime and various other companies and foundations.

July 2020

CimCure and Intravacc announce the signing of a strategic partnership agreement. They will jointly develop a COVID-19 vaccine based on CimCure’s iBoost technology and provide a boost for the development of novel infectious disease and oncology vaccines.

May 2020

Financial support of 1351 k€ from HEALTH-HOLLAND to Amsterdam University Medical Center and CimCure B.V. for the generation of a targeted vaccine against critical domains in the spike protein of SARS-CoV-2, to be used for current and future coronaviruses based on CimCure’s iBoost technology.

March 2020

Pharmatide is lead investor for Cimcure’s pre-seed funding round that it expects to close shortly. Subsequently  Pharmatide will lead the next financing round planned for closure around the end of 2020.

March 2019

Financial support of 275 k€ from HEALTH-HOLLAND for generation of a preventive cancer vaccine. This grant supports CimCure on the proof-of-principle for using its iBoost vaccine platform for the development of a multi-targeted vaccine against the tumor vasculature.


March 2018

Publication Huijbers et al. accepted by Vaccine. See Huijbers et al, 2018. This paper demonstrates the value of CimCure’s proprietary technology immuno-Boost (iBoost).

November 2017

Proof of Concept grant (100 k€) of the Dutch government and the VU/VUMC TTO office. This grant supports CimCure on the demonstration of the validity of cancer prevention by vaccination against very early vascular markers of tumor angiogenesis.

September 2016

Publication Wentink et al. accepted by Proceeding of the National Academy of Sciences of the USA. See Wentink et al, 2016. This report from the Angiogenesis Laboratory demonstrates the validity of CimCure’s approach of anti-angiogenic vaccination strategies.